Evaluation of ceruloplasmin - a potential biomarker in chronic heart failure

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F18%3A00007791" target="_blank" >RIV/00023884:_____/18:00007791 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.4172/2155-9880.1000601" target="_blank" >http://dx.doi.org/10.4172/2155-9880.1000601</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4172/2155-9880.1000601" target="_blank" >10.4172/2155-9880.1000601</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Evaluation of ceruloplasmin - a potential biomarker in chronic heart failure

Popis výsledku v původním jazyce

Background: Ceruloplasmin (Cp) is an acute phase protein with plasma copper binding properties and is involved in inflammatory processes and oxidative stress. Cp may play a role in the pathophysiology of heart failure. Study objective: to analyse relation of Cp with disease severity in patients with chronic stable heart failure as assessed by clinical and laboratory parameters Patients and methods: Serum levels of Cp, NT-proBNP and other biochemical parameters were analysed in 164 consecutive patients with chronic stable heart failure (CHF group). Consecutive 64 patients with arterial hypertension (AH group) without heart failure served as a control group. Results: Mean Cp level in CHF group was 230 mg/l and 200 mg/l in AH group (p < 0.001), mean NT-proBNP was 1843 pg/ml in CHF and 139 pg/ml AH (p < 0.001). Cp correlated with NT-proBNP in HF (r = 0.323, p < 0.001) in CHF group significantly and in AH group not significantly (r = 0.222, p = 0.08). Cp correlated significantly with total bilirubin (r = 0.213, p = 0.0067) and with albumin (inverse correlation r = - 0.273, p = 0.0005). Cp level correlated with functional class NYHA (r = 0.230, p = 0.0034) and LV EF (inverse correlation – 0.237, p = 0.0025) too. Cp correlated in both groups (n = 228) with NT-proBNP significantly (r = 0.349, p < 0.0001). Conclusion: Cp in patients with stable CHF correlates with disease severity as assessed by the level of NT-proBNP, functional class NYHA, LV EF, bilirubin and albumin.

Název v anglickém jazyce

Evaluation of ceruloplasmin - a potential biomarker in chronic heart failure

Popis výsledku anglicky

Background: Ceruloplasmin (Cp) is an acute phase protein with plasma copper binding properties and is involved in inflammatory processes and oxidative stress. Cp may play a role in the pathophysiology of heart failure. Study objective: to analyse relation of Cp with disease severity in patients with chronic stable heart failure as assessed by clinical and laboratory parameters Patients and methods: Serum levels of Cp, NT-proBNP and other biochemical parameters were analysed in 164 consecutive patients with chronic stable heart failure (CHF group). Consecutive 64 patients with arterial hypertension (AH group) without heart failure served as a control group. Results: Mean Cp level in CHF group was 230 mg/l and 200 mg/l in AH group (p < 0.001), mean NT-proBNP was 1843 pg/ml in CHF and 139 pg/ml AH (p < 0.001). Cp correlated with NT-proBNP in HF (r = 0.323, p < 0.001) in CHF group significantly and in AH group not significantly (r = 0.222, p = 0.08). Cp correlated significantly with total bilirubin (r = 0.213, p = 0.0067) and with albumin (inverse correlation r = - 0.273, p = 0.0005). Cp level correlated with functional class NYHA (r = 0.230, p = 0.0034) and LV EF (inverse correlation – 0.237, p = 0.0025) too. Cp correlated in both groups (n = 228) with NT-proBNP significantly (r = 0.349, p < 0.0001). Conclusion: Cp in patients with stable CHF correlates with disease severity as assessed by the level of NT-proBNP, functional class NYHA, LV EF, bilirubin and albumin.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical & Experimental Cardiology

ISSN

2155-9880

e-ISSN

—

Svazek periodika

9

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—